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http://dx.doi.org/10.1016/j.bgm.201
2214-0247/Copyright ª 2014, TaiwanAbstract For 2 decades, lung cancer has been the most deadly of all malignant neoplasms in
Taiwan. Novel strategies for the discovery and treatment of lung cancers are becoming a
particularly important research topic in the field of biomedicine. Gefitinib (trade name Iressa;
AstraZeneca, Wilmington, DE, USA) is a biologic agent used to treat lung cancer. The clinical
antitumor action of gefitinib is primarily the inhibition of the epidermal growth factor recep-
tor. Gefitinib is indicated as a first-line therapy for lung cancer, although the occurrence of
chemoresistance limits the longterm results of this drug. This study was divided into two
research directions. The first part is to generate the drug-resistant cancer cell line as a plat-
form to understand the mechanism of drug inactivation of gefitinib for lung cancer. The second
part is to collect cell secretomes to find potential biomarkers for the diagnosis and treatment
of lung cancer by using minimally invasive assays. Therefore, the non-small-cell lung carci-
noma line PC9 and gefitinib-resistant cancer cell line PC9/gef were used in this study. With
the analysis of secretomics, differentially expressed extracellular secreted proteins were iden-
tified to study the desired biomarkers for molecular diagnostics and gefitinib-resistance. These
cell lines provide a useful tool for the further study of the biologic properties in lung cancer
in vitro.
Copyright ª 2014, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.of Applied Science, National Hsinchu University of Education, Number 521, Nan-Da Road, Hsinchu,
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Lung cancer is one of the most difficult cancers to treat.
According to the international statistics on lung cancer
survival rates, the overall 5-year survival rate for stage I
and stage II lung cancers is 30e50% and the overall 5-year
survival rate for stage III and stage IV lung cancers is
<10%. Lung cancer patients in the early stage of this
disease have a high survival rate; however, most patients
are diagnosed with lung cancer at an advanced stage.1
That is why the mortality rate of lung cancer is always
high. Gefitinib is a first-line cancer drug for treating lung
cancer. By reversibly competing with adenosine triphos-
phate (ATP), gefitinib is able to bind into a critical ATP
binding site to inhibit intracellular tyrosine kinase activity
of the epidermal growth factor receptor (EGFR), which
inhibits cancer cell growth.2 Acquired resistance to gefi-
tinib nevertheless has been reported in patients after a
median of approximately 10 months from the initiation of
treatment.3 By contrast, a secretome represents all pro-
teins secreted by cells. Many secreted proteins such as
cytokines, growth factors, angiogenesis factors, and pro-
teases are important in the progression of tumors and
their signal transduction. By collecting the secretomes
and performing two-dimensional differential gel electro-
phoresis (2D-DIGE) analysis and matrix-assisted laser
desorption/ionization-time of flight (MALDI-TOF) analysis
to find the proteins that are expressed differentially be-
tween the cancer cell line and the drug-resistant cell line,
we hope to establish a system with a noninvasive mode to
investigate the biomarkers for gefitinib-resistant lung
cancer, and thereby improve overall survival rates in
patients.Figure 1 The MTT assay results. The PC9 and PC9/gef cells
were grown overnight and treated with a range of doses of
gefitinib. An MTT assay is used to determine cell viability.
MTT Z 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide.Materials and methods
Cell line and culture
Cell lines used in this study were human lung cell line PC9
(American Type Culture Collection, Manassas, VA USA) and
its gefitinib-selected drug-resistant cell line, PC9/gef. The
PC9 and PC9/gef cells were cultured at 37C and 5% carbon
dioxide (CO2) in Roswell Park Memorial Institute (RPMI)
medium with 1.5 g/L sodium bicarbonate containing 10%
(v/v) fetal bovine serum, and 1 IU/mL penicillin/strepto-
mycin (all items were purchased from Gibco-Invitrogen
Corp., Paisley, UK).
MTT cell viability assay
Cells were seeded in 96-well plates (8000 cells/well) and
incubated for 24 hours, prior to treating them with the
indicated gefitinib concentrations for 48 hours. After
removing gefitinib, 100 mL of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) reagent (1 mg/mL)
were added to each well and incubated at 37C at 5% CO2
for 4 hours. The supernatant was removed and 100 mL
dimethyl sulfoxide (DMSO) was added to stop the reaction.
The absorbance of the samples was measured at a wave-
length of 545nM.Time course of the starve
Cell lines were incubated in serum-free RPMI medium.
The cell culture medium was harvested at the indicated
hours to collect the secretome. The Western blot test was
used to ensure that the cell was intact. (The secretome
needs to be collected before the cell is destroyed during
starvation.)
Collecting the secretome
The secretome was collected from three 15-cm Petri dishes
and then centrifuged at 2683.2 g for 90 minutes until the
supernatant was concentrated to 1 mL.
Western blot
Protein samples were diluted with sample buffer and
separated by 10% sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE). After transferring the
separated proteins to Immobilon-P membranes (with a pore
size of 0.45 mm), the membranes were blocked for 1 hour
by 5% bovine serum albumin (BSA). The membranes were
then incubated with primary antibody against asparagine
synthetase (ASNS) for 24 hours and washed with tris-
buffered saline and Tween 20 (TBS-T; 4 10 minutes).
They were thereafter incubated with secondary antibody
for 1 hour and washed again with TBS-T (6  15 minutes).
Immunoreactive proteins were detected by a chem-
iluminescence method.
Two dimensional-differential gel electrophoresis
analysis
Two dimensional-differential gel electrophoresis analysis
was performed with cyanine dyes containing Cy2, Cy3, and
Figure 2 The expression of the intracellular protein LDH of
the PC9 and PC9/gef cells is shown at 0 hours, 24 hours, 30
hours, 48 hours, 54 hours, and 72 hours. Water (H2O) is the
positive control for the presence of cell lyses.
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with Cy3 and Cy5. All samples were labeled with Cy2, which
was an internal standard to all gels. The labeled samples
were incubated in the dark for 30 minutes on ice. The
reaction was then stopped by the addition of L-lysine. The
Cy3- and Cy5-labeled samples were combined and mixed in
an equal volume with the Cy2-labeled internal standard.
After adding dithiothreitol (DTT) and carrier ampholyte
immobilized pH gradient (IPG) buffer, the final volume was
adjusted to 450 mL with 2D-lysis buffer. Nonlinear strips
(pH 3e10, 24 cm) were rehydrated by CyDye-labeled sam-
ples in the dark at room temperature overnight. Two-
dimensional DIGE and gel analysis were performed, andFigure 3 Two-dimensional differential gel electrophoresis (2D-D
proteins, the middle image shows the location of the PC9/gef pro
images (green is PC9 and red is PC9/gef). (B) The left image shows th
location of the PC9 proteins, and the right images shows the merge
is PC9). (C) The left image shows the location of the PC9 proteins, th
the right image shows the merged PC9 and PC9/gef fluorescent im
represents three repeats of cell samples for this experiment.DeCyder software (GE Healthcare, Uppsala, Sweden) was
used for 2D differential analysis.
Protein analysis
The interested proteins on the 2D gel were subjected to in-
gel digestion. The peptide samples were dissolved in 0.1%
trifluoroacetic acid (TFA), spotted onto an anchor chip
target plate, covered the a-cyano-4-hydroxycinnamic acid
(HCCA) matrix after the samples dried. The peptide mass
fingerprint was analyzed by a MALDI-TOF-mass spectrom-
eter (MALDI-TOF-MS) (Bruker Daltonics Inc., Bremen, Ger-
many), and Mascot search software (Matrix Science,
London, UK) was used to identify these proteins.
Statistical analysis
Statistical analyses were performed using the two-tailed
Student t test. A value of p < 0.05 was considered statis-
tically significant.
Results
Cell viability of PC9 and PC9/gef cells
Fig. 1 shows the cell viability of the PC9 and PC9/gef cells
with the treatment of different gefitinib concentrations.IGE) images. (A) The left image shows the location of the PC9
teins, and the right image shows the merged PC9 and PC9/gef
e location of the PC9/gef proteins, the middle image shows the
d PC9 and PC9/gef fluorescent image (green is PC9/gef and red
e middle image shows the location of the PC9/gef proteins, and
age (green is PC9 and red is PC9/gef). The gel arrangement
Figure 4 The two-dimensional differential gel electropho-
resis (2D-DIGE) gel images. The x axis shows the PI value, which
descends from left to right. The y axis shows the molecular
weight, the value of which descends from top to bottom. A
total of 2388 protein spots with a change of at least 1.5-fold
are shown (p  0.05).
Figure 5 Differentially expressed proteins, as identified by
lysine-labeling 2D-DIGE/MALDI-TOF-MS analysis in PC9 cells and
PC9/gef cells. 2D-DIGE Z two-dimensional differential gel
electrophoresis; MALDI-TOF-MS Z matrix-assisted laser
desorption/ionization-time of flight/mass spectroscopy.
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PC9/gef and PC9 cells was 266.7-fold.
PC9 and PC9/gef cells in the time course of the
starve
Fig. 2 shows the time course of the starve. Based on the
Western blot of the intracellular protein lactatedehydrogenase (LDH), a 24-hour starvation period was
selected to collect secreted proteins in the medium of the
culture supernatant to avoid contamination by cytoplasmic
proteins.PC9 and PC9/gef cells in proteomics analysis
To investigate the differentially expressed proteins that
participate in the development of gefitinib resistance,
secreted proteins from PC9 and PC9/gef cells were
labeled with lysine-labeling cyanine (Cy) dyes and sepa-
rated by the 2D-DIGE method (Fig. 3). A total of 2388
protein spots showed a change greater than 1.5-fold
(p < 0.5). Of these, 395 protein spots were selected and
digested with trypsin. Based on the MALDI-TOF-MS and
Mascot search, 135 interested proteins were identified, as
shown in Fig. 4.
These identified proteins were categorized according to
their biological functions. Most protein functions were
involved in transcription regulation, cytoskeleton, signal
regulation, and glycolysis. Fig. 5 shows the analysis.Discussion
Numerous secreted proteins have been identified by using
2D-DIGE and MALDI-TOF-MS to analyze comparatively the
secretome of gefitinib resistance in a lung cancer cell line.
For instance, the 14-3-3 protein family was upregulated in
the PC9/gef cells, based on the 2D-DIGE results. Because
14-3-3 proteins modulate many cellular processes that are
important in cancer biology and 14-3-3 protein epsilon and
14-3-3 protein beta in the resistant cells may account for
cancer progression,4 our observation suggests that the 14-3-
3 family may be an important protein in the regulation of
gefitinib drug resistance.Conflicts of interest
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